tbuckley/cabot-search huggingface dataset:
DNA Methylation Profiles Suggest Intergenerational Transfer of Maternal Effects
Authors: Clare J Venney, Oliver P Love, Ellen Jane Drown, Daniel D Heath
Journal: Molecular Biology and Evolution (2019)

The view of maternal effects (nongenetic maternal environmental influence on offspring phenotype) has changed from one of distracting complications in evolutionary genetics to an important evolutionary mechanism for improving offspring fitness. Recent studies have shown that maternal effects act as an adaptive mechanism to prepare offspring for stressful environments. Although research into the magnitude of maternal effects is abundant, the molecular mechanisms of maternal influences on offspring phenotypic variation are not fully understood. Despite recent work identifying DNA methylation as a potential mechanism of nongenetic inheritance, currently proposed links between DNA methylation and parental effects are indirect and primarily involve genomic imprinting. We combined a factorial breeding design and gene-targeted sequencing methods to assess inheritance of methylation during early life stages at 14 genes involved in growth, development, metabolism, stress response, and immune function of Chinook salmon (Oncorhynchus tshawytscha). We found little evidence for additive or nonadditive genetic effects acting on methylation levels during early development; however, we detected significant maternal effects. Consistent with conventional maternal effect data, maternal effects on methylation declined through development and were replaced with nonadditive effects when offspring began exogenous feeding. We mapped methylation at individual CpG sites across the selected candidate genes to test for variation in site-specific methylation profiles and found significant maternal effects at selected CpG sites that also declined with development stage. While intergenerational inheritance of methylated DNA is controversial, we show that CpG-specific methylation may function as an underlying molecular mechanism for maternal effects, with important implications for offspring fitness.
P1.01-82 The Different Frequencies and Genetic Profiles of Histologic Transformation After Different EGFR-TKIs in EGFR-Mutant Adenocarcinomas
Authors: J. Kang, H. Chen, B. Wang, Z. Wang, X. Zhang, X. Li, Q. Deng, Y. Wu, J. Yang
Journal: Journal of Thoracic Oncology (2019)
Abstract 524: HMGB1-activated IRF3 and NF-κB contributes to UV radiation-induced immune suppression by upregulating PD-L1
Authors: Wei Wang, Nicole Chapman, Bo Zhang, Mingqi Li, Meiyun Fan, R. Nicholas Laribee, M. Raza Zaidi, Lawrence Pfeffer, Hongbo Chi, Zhaohui Wu
Journal: Cancer Research (2019)

Abstract Solar ultraviolet radiation (UVR) suppresses skin immunity, which facilitates skin lesion initiation and establishment by promoting immune evasion. It is unclear whether immune checkpoints are involved in the modulation of skin immunity by UVR. Here we report that the expression of immune checkpoint molecule PD-L1 was significantly increased in melanocytes and melanoma cells upon UVR exposure. The damage-associated molecular patterns molecule HMGB1 was secreted by melanocytes and keratinocytes upon UVR, which subsequently activated the RAGE (receptor for advanced glycation endproducts) receptor to promote the NF-κB and IRF3-dependent transcription of PD-L1 in melanocytes. We also found that UVR exposure significantly reduced the susceptibility of melanoma cells to CD8+ T cell-dependent cytotoxicity, which was mitigated by inhibiting the HMGB1/TBK1/IRF3/NF-κB cascade or blocking the PD-1/PD-L1 checkpoint. Taken together, our findings demonstrate that UVR-induced PD-L1 upregulation contributes to the immune suppression in the skin microenvironment, which may promote immune evasion of oncogenic cells, and melanoma initiation and progression. Citation Format: Wei Wang, Nicole Chapman, Bo Zhang, Mingqi Li, Meiyun Fan, R. Nicholas Laribee, M. Raza Zaidi, Lawrence Pfeffer, Hongbo Chi, Zhaohui Wu. HMGB1-activated IRF3 and NF-κB contributes to UV radiation-induced immune suppression by upregulating PD-L1 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 524.
(循環器病の診断と治療に関するガイドライン (2006-2007年度合同研究班報告)) : 血管炎症候群の診療ガイドライン
Authors: 循環器病の診断と治療に関するガイドライン作成班 日本循環器学会, 太三 安藤, 克夫 居石, 光章 磯部, 敬 太田, 茂人 小林, 宏 重松, 和雄 種本, 康雄 中島, 公正 中林, 眞人 能勢, 尚文 松永, 哲郎 宮田, 親夫 由谷, 雅治 吉田, 晃敏 吉田, 義宏 有村, 明洋 石津, 武尚 岩井, 貴裕 岡崎, 宗正 岡田, 浩 片岡, 一成 金子, 誠司 川名, 一成 木田, 泰之 小林, 公浩 古森, 一郎 坂本, 紀彦 椎谷, 邦広 重松, 淳士 高橋, 始 滝澤, 泰司 長岡, 浩平 長澤, 美久 野島, 博史 橋本, 真吾 濱口, 桂樹 廣村, 修作 深谷, 久男 正木, 常男 松本, 秀裕 山田, 俊治 吉田, 俊一 熊谷, 隆夫 小池, 唯博 笹嶋, 次矢 福井, 稔 堀江
Journal: Circulation (2008)
EP1.12-14 Multiple Primary Malignant Neoplasms in Patients with Small Cell Lung Cancer. The Experience of Our Center
Authors: M. Vaslamatzis, T. Tegos, N. Alevizopoulos, M. Pavlakis, K. Karagiorgou, E. Patila, K. Gioti, D. Exarchos, C. Zisis
Journal: Journal of Thoracic Oncology (2019)
Association of Metabolically Healthy Overweight Phenotype With Abnormalities of Glucose Levels and Blood Pressure Among Chinese Adults
Authors: Renying Xu, Xiang Gao, Yanping Wan, Zhuping Fan
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Whether the metabolically healthy overweight (MHO) phenotype is resistant to metabolic abnormalities remains unknown. <h3>Objective</h3> To evaluate the association of MHO with glucose level abnormalities and high blood pressure (BP) in Chinese adults. <h3>Design, Setting, and Participants</h3> This prospective cohort study was conducted from January 1, 2013, to October 31, 2018, in the Health Management Center at Ren Ji Hospital, Shanghai, China, using data from 55 155 recruited Chinese adults. Body weight, fasting blood glucose (FBG) level, hemoglobin A<sub>1c</sub>(HbA<sub>1c</sub>) level, and BP were measured annually. <h3>Exposures</h3> Metabolically healthy overweight was defined as a body mass index (calculated as weight in kilograms divided by height in meters squared) of 24.0 in 2013 (baseline) and 2014, no history of metabolic diseases, and normal FBG level, HbA<sub>1c</sub>level, BP, lipid profile, serum uric acid level, and liver ultrasonographic findings at baseline; the remaining participants were defined as being metabolically healthy normal. <h3>Main Outcomes and Measures</h3> Glucose level abnormality was confirmed if the FBG level was 101 mg/dL or greater or the HbA<sub>1c</sub>level was 5.7%, and high BP was confirmed if the systolic BP was 130 mm Hg or higher or the diastolic BP was 80 mm Hg or higher at least twice during the subsequent 4 years of follow-up. <h3>Results</h3> A total of 3204 metabolically healthy Chinese adults (mean [SD] age, 39.8 [10.9] years; 1940 women [60.5%]) were included in the study. The prevalence of MHO was 7.0%. A total of 146 incident cases of glucose level abnormality and 220 cases of high BP during 4 years of follow-up were identified. Compared with the metabolically healthy normal group, the MHO group had a higher risk of glucose level abnormality (adjusted hazard ratio, 2.36; 95% CI, 1.52-3.64) and high BP (adjusted hazard ratio, 1.73; 95% CI, 1.18-2.53) after adjusting for several potential confounders. <h3>Conclusions and Relevance</h3> Metabolically healthy overweight may be associated with a high future risk of glucose abnormality and high BP in Chinese adults. If the individuals are confirmed with MHO, early interventions, including diet and exercise, should be recommended to decrease the risk of developing abnormalities of glucose and BP.
P1.01-03 Efficacy and Safety of Biosimilar QL1101 Compared with Avastin in Patients with Non-Squamous Non-Small Cell Lung Cancer
Authors: B. Han, K. Li, T. Chu, M. Bi, H. Zhang, Y. Yu, J. Shi, X. Zhang, Z. Chen, C. Han, T. Bai
Journal: Journal of Thoracic Oncology (2019)
MA13.02 Incidence of Venous Thromboembolism at the Time of Lung Cancer Diagnosis: A Multicenter, Prospective Observational Trial (Rising-VTE/NEJ037)
Authors: Y. Tsubata, K. Hamai, N. Furuya, T. Hata, R. Saito, T. Masuda, T. Hotta, M. Hamaguchi, S. Kuyama, R. Honda, K. Nakano, M. Nakanishi, K. Funaishi, M. Yamasaki, N. Ishikawa, K. Fujitaka, T. Kubota, K. Kobayashi, T. Isobe
Journal: Journal of Thoracic Oncology (2019)
MA19.07 Testing an Optimal Care Coordination Model (OCCM) for Lung Cancer in a Multi-Site Study
Authors: M. Smeltzer, T. Asfeldt, N. Faris, A. Kramar, C. Amorosi, V. Nolan, M. Ray, M. Dawkins, M.C. Nalan, W. Stevens, L. Lucas, R. Oyer, C. Lathan, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2019)
Transcriptome of DNA Repair Genes in CMML: Rationale for Targeting ERCC1 and CDKN1A As a Synthetic Lethality Approach
Authors: Ana M Hurtado, Ginés Luengo-Gil, Tzu Hua Chen-Liang, Fabio Amaral, Laura Palomo, Eva Lumbreras, Bartlomiej Przychodzen, Eva Caparrós, Maria Luz Amigo, Maria Díez-Campelo, Lurdes Zamora, Eduardo José Salido, Jaroslaw P. Maciejewski, Francisco José Ortuño, Vicente Vicente, Consuelo Del Cañizo, Francesc Sole, Francisca Ferrer Marin, Daniel Wiseman, Andres Jerez
Journal: Blood (2017)
P2.14-16 T790M or C797S Confers Acquired Resistance to Tarloxotinib and Poziotinib in EGFR Exon 20 Insertion-Driven Lung Cancer Models in Vitro
Authors: K. Suda, M. Nishino, T. Koga, T. Fujino, S. Ohara, J. Soh, A. Vellanki, V. Tirunagaru, T. Misudomi
Journal: Journal of Thoracic Oncology (2019)
MA09.10 Comprehensive Analysis of Secondary Mutation as Resistance Mechanism to Seven MET-TKIs for MET Exon 14 Skipping in Vitro
Authors: T. Fujino, Y. Kobayashi, K. Suda, T. Koga, M. Nishino, S. Ohara, M. Chiba, A. Hamada, T. Takemoto, J. Soh, T. Misudomi
Journal: Journal of Thoracic Oncology (2019)
P1.01-122 A Clinical Utility Study of Plasma DNA Next Generation Sequencing Guided Treatment of Uncommon Drivers in Advanced Non-Small-Cell Lung Cancers
Authors: H. Tu, C. Xu, C. Tong-Li, M. Offin, P. Razavi, E. Schapira, A. Namakydoust, A. Lee, N. Pavlakis, S. Clarke, C. Diakos, D. Chan, M. Myers, A. Makhnin, H. Jain, A. Martinez, Z. Iqbal, A. Adamski, H. Li, J. Hernandez, S. Watford, A. Hosseini, T. Shaffer, L. Lim, M. Li, A. Drilon, M. Ladanyi, M. Arcila, V. Rusch, D. Jones, C. Rudin, A. Rimner, J. Isbell, B. Li
Journal: Journal of Thoracic Oncology (2019)
EP1.09-06 An Unusual Diagnostic Case of Hypoglycemia: A Different Perspective of the Doege-Potter Syndrome
Authors: S. Congiu, M.T. Migliano, D. Giunta, G. Dolci, A. Gramenzi, V. Vicennati, M.G. Pirini, V. Ambrosini, F. Trevisani, N. Daddi
Journal: Journal of Thoracic Oncology (2019)
Evaluation of p16/Ki-67 dual-stain cytology performed on self-collected vaginal and clinician-collected cervical specimens for the detection of cervical pre-cancer
Authors: P.J. Toliman, S. Phillips, S. de Jong, T. O'Neill, G. Tan, J.M.L. Brotherton, M. Saville, J.M. Kaldor, A.J. Vallely, S.N. Tabrizi
Journal: Clinical Microbiology and Infection (2019)
P2.01-12 A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC
Authors: M. Provencio, J. Spicer, P. Garrido, J.M. Trigo Perez, S. Viteri, J. Bosch-Barrera, A. Insa, E. Felip, J. De Castro Carpeno, E. Coart, E. Schmidt, A. Christiansen, M. Hald Andersen, M. Zocca, E. Ehrnrooth, L. Paz-Aras
Journal: Journal of Thoracic Oncology (2019)
A phase II feasibility study of cytarabine and idarubicin combination in relapsed or refractory adult acute lymphoblastic leukemia
Authors: M. Hafeez, A. Shaharyar, N. Zia, H. Rasheed
Journal: Journal of Clinical Oncology (2009)

e18002 Background: Most patients with adult ALL eventually relapse. Salvage regimens in these patients and in patients with primary refractory disease are generally based on cytarabine in combination with other agents. Exact merit of each combination remains undefined as these continue to be tested in non randomized trials. This study was conducted with the objectives to find out the efficacy and toxicity of cytarabine and idarubicin combination. Methods: From December 2006 to March 2008, 30 patients were enrolled in this prospective, nonrandomized single institution phase II feasibility study. It was empirically decided that the study will only be considered feasible if more then ten patients achieve a complete remission. Patients who relapsed during maintenance therapy or were refractory and were at least 16-years-old were considered eligible provided they have received at least vincristine and prednisone as induction. No prior cytarabine was allowed. Cytarabine 100 mg/m 2 continuous infusion for seven days along with idarubicin 12 mg/m 2 day 1 to 3, IV bolus was given. Bone marrow examination was done 15 days after the completion of chemotherapy. Results: All thirty patients completed planned treatment. Five patients died of infection during treatment. Eleven patients achieved complete remission. All patients relapsed within eight months. Conclusions: The regimen of cytrarabine and idarubicin is feasible and sufficiently effective in relapsed or refractory adult ALL with manageable toxicity. No significant financial relationships to disclose.
P1.01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study
Authors: A. Qin, S. Zhao, A. Miah, L. Wei, S. Patel, A. Johns, M. Grogan, E. Bertino, K. He, S. Olugbile, P. Shields, G. Kalemkerian, S. Gadgeel, N. Ramnath, B. Schneider, K. Hassan, D. Carbone, C. Presley, G. Otterson, D. Owen
Journal: Journal of Thoracic Oncology (2019)
MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC
Authors: L. Mezquita, P. Martin-Romano, E. Auclin, B. Duchemann, L. Cassard, D. Planchard, M. Naigeon, I. Gataa, M. Charrier, R. Ferrara, L. Boselli, J. Grivel, M. Ngocamus, J. Adam, N. Chaput, B. Besse
Journal: Journal of Thoracic Oncology (2019)
MA21.09 Tyrosine Kinase Inhibitors' Plasma Concentration and Oncogene-Addicted Advanced Non-Small Lung Cancer (aNSCLC) Resistance
Authors: A. Geraud, L. Mezquita, E. Auclin, D. Combarel, J. Delahousse, C. Naltet, C. Jovelet, P. Lavaud, A. Gazzah, L. Lacroix, J. Remon, C. Caramella, D. Planchard, O. Mir, A. Paci, B. Besse
Journal: Journal of Thoracic Oncology (2019)
P2.03-17 Optimization of an Ex-Vivo Preclinical Model for Drug Testing
Authors: E. Marin, P. Duch, M. Gabasa, E. Urrea, R. Ikemori, N. Díaz-Valdivia, C. Teixido, N. Reguart, J. Alcaraz
Journal: Journal of Thoracic Oncology (2019)
P2.17-17 Clinical Effect of Adjuvant Chemotherapy on Stage IB NSCLC with High-Risk Factors
Authors: J. Choi, S.I. Choi, J.Y. Oh, Y.S. Lee, K.H. Min, G.Y. Hur, J.J. Shim, D.W. Park, C.K. Park, S. Lee
Journal: Journal of Thoracic Oncology (2019)
Macrophages reprogrammed by lung cancer microparticles promote tumor development via release of IL-1β
Authors: Jie Chen, Weiwei Sun, Huafeng Zhang, Jingwei Ma, Pingwei Xu, Yuandong Yu, Haiqing Fang, Li Zhou, Jiadi Lv, Jing Xie, Yuying Liu, Ke Tang, Bo Huang
Journal: Cellular and Molecular Immunology (2019)

Abstract Despite their mutual antagonism, inflammation and immunosuppression coexist in tumor microenvironments due to tumor and immune cell interactions, but the underlying mechanism remains unclear. Previously, we showed that tumor cell-derived microparticles induce an M2 phenotype characterized by immunosuppression in tumor-infiltrating macrophages. Here, we further showed that lung cancer microparticles (L-MPs) induce macrophages to release a key proinflammatory cytokine, IL-1β, thus promoting lung cancer development. The underlying mechanism involves the activation of TLR3 and the NLRP3 inflammasome by L-MPs. More importantly, tyrosine kinase inhibitor treatment-induced L-MPs also induce human macrophages to release IL-1β, leading to a tumor-promoting effect in a humanized mouse model. These findings demonstrated that in addition to their anti-inflammatory effect, L-MPs induce a proinflammatory phenotype in tumor-infiltrating macrophages, promoting the development of inflammatory and immunosuppressive tumor microenvironments.
Transfection of human prostate cancer cells (DU145) with the human short prolactin receptor sensitizes the cells to cell cycle regulation by S179D prolactin
Authors: Wei Wu, Barbara K. Vonderhaar, Ameae M. Walker
Journal: Cancer Research (2004)

1943  Previous work from this laboratory has demonstrated that a molecular mimic of naturally phosphorylated prolactin, S179D PRL, inhibited cell growth in several human prostate cancer lines in vitro and the growth of DU145 cells when grown as tumors in nude mice (Cancer Res 61:6098,2001). In part, the growth inhibition is by blockade of an autocrine unmodified prolactin (U-PRL) growth loop working through the long PRL receptor, but several lines of data suggest additional mechanisms. In this study, we have further investigated the molecular mechanism of this growth inhibition by comparing the more differentiated, lower autocrine U-PRL-producing LnCAP cell line with the less differentiated, higher autocrine U-PRL-producing DU145 cell line. LnCAP and DU145 cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) or 10% charcoal-stripped FBS and, when confluent, were treated with 1 μg/ml U-PRL, S179D PRL or diluent for 3 days (daily medium change). Response to S179D PRL differed between the two cell lines. In the LnCAP cells, but not the DU145 cells, S179D PRL, but not U-PRL, had a long term effect on the activation of ERKs 1 and 2 (>5 fold at 3 days)and upregulated the expression of the vitamin D receptor (VDR) (3 fold, p
Surgery-induced peritoneal metastasis and its intraoperative treatment.
Authors: Satoshi Murata, Katsushi Takebayashi, Masatsugu Kojima, Hiroshi Yamamoto, Tsuyoshi Yamaguchi, Hiroyuki Naitoh, Mitsuaki Ishida, Eiji Mekata, Tomoharu Shimizu, Hisanori Shiomi, Hiromichi Sonoda, Shigeyuki Naka, Tsuyoshi Mori, Hiroya Akabori, Koichiro Murakami, Tomoyuki Ueki, Aya Mizuno, Hajime Abe, Hidetoshi Okabe, Tohru Tani
Journal: Journal of Clinical Oncology (2013)

4092 Background: A large number of advanced gastric cancer patients undergoing curative gastrectomy with D2 lymph node dissection (D2 gastrectomy) show peritoneal metastasis. The source of these metastatic cells and their treatment remain unclear. We examined the mechanism of surgery-induced peritoneal metastasis and determined the appropriate intraoperative treatment. Methods: (1) Curative gastrectomy was performed for 102 gastric cancer patients. Peritoneal lavage fluid was collected before and after gastrectomy. Cytology, RT-PCR, and cell culture were used to determine the presence of cancer cells. Proliferative potential of tumor cells was evaluated using Ki-67 staining. Tumorigenic capacity was assessed by cell injection into the peritoneal cavity of NOD/ShiJic-scid mice. (2) Fifty clinical T3(SE) or T4(SI) advanced gastric cancer patients undergoing curative D2 gastrectomy prospectively received intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in a phase II trial. HIPEC comprised 50 mg CDDP, 10 mg MMC, and 1000 mg 5-FU in 5 L saline maintained at 42–43C° for 30 min. Results: (1) Of 102 peritoneal lavage fluid samples obtained before gastrectomy, 57 from both early and advanced cancer patients did not contain CEA or CK20 mRNA amplification products or cancer cells. Of these 57 samples, CEA or CK20 mRNA was detected in 35 and viable cancer cells were identified in 24 after gastrectomy. Viable cancer cells in all 24 cases showed Ki-67 positivity, indicating proliferative activity. Cultured viable cancer cells developed into peritoneal tumor nodules after spill over into the peritoneal cavity in NOD/ShiJic-scid mice. (2) Fifty patients were eligible for the phase II clinical trial. The overall 5-year survival rate for all patients was 92.4%. This rate in patients with pT2(ss) (n = 12), pT3(se) (n = 35), and pT4(si) (n = 3) disease was 90.0%, 92.3%, and 100%, respectively. Only 2 patients (4%) showed peritoneal relapse. Conclusions: Viable tumorigenic cancer cells spilled over the peritoneal cavity during curative gastrectomy. Intraoperative HIPEC following curative D2 gastrectomy effectively prevented peritoneal metastasis, thereby potentially improving the prognosis of patients with advanced gastric cancer.
MA11.07 Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
Authors: K. Masuda, H. Horinouchi, M. Tanaka, R. Higashiyama, Y. Shinno, J. Sato, T. Yoshida, Y. Matsumoto, Y. Goto, S. Kanda, N. Yamamoto, Y. Ohe
Journal: Journal of Thoracic Oncology (2019)
P2.09-10 INSM1 Is a Good Marker for Diagnosis of Small Cell Lung Carcinoma Even When Neuroendocrine Marker Negative
Authors: R. Sakakibara, M. Kobayashi, R. Wakejima, N. Takahashi, K. Inamura, H. Ninomiya, S. Kitazono, N. Yanagitani, A. Horiike, J. Ichinose, Y. Matsuura, M. Nakao, M. Mun, M. Nishio, S. Okumura, N. Motoi, T. Ito, Y. Miyazaki, N. Inase, Y. Ishikawa
Journal: Journal of Thoracic Oncology (2019)
P1.04-30 Pioneer Study: Precision Immuno-Oncology for Advanced Non-Small Cell Lung Cancer Patients with PD1/L1 ICI Resistance
Authors: F. Barlesi, D. Pérol, J. Mazieres, M. Perol, N. Varoqueaux, F. Monville, C. Audigier-Valette, P. Barre, F. Domergue, L. Falchero, C. Foa, A. Frikha, S. Hominal, J. Le Treut, S. Zahi, M. Roumieux, D. Olive, E. Vivier
Journal: Journal of Thoracic Oncology (2019)
P2.11-13 What Is the Impact of Localised Data When Training Deep Neural Networks for Lung Cancer Prediction?
Authors: A. Devaraj, I. Pulzato, S. Kemp, C. Ridge, S. Padley, A. Nicholson, C. Arteta, P. Novotny, L. Pickup, J. Declerck, T. Kadir
Journal: Journal of Thoracic Oncology (2019)
P1.03-33 Analysis of Lipid Metabolism Genes in Advanced Small Cell Lung Cancer
Authors: M. Merino, L.P. Fernández, M. Sereno Moyano, A. Ramírez De Molina, J. Moreno Rubio, G. Colmenarejo, C. Gómez Raposo, M. López Gómez, S. Falagán Martínez, C. Aguayo Zamora, F. Zambrana Tévar, A.M. Jiménez Gordo, E. Casado Sáez
Journal: Journal of Thoracic Oncology (2019)
P2.03-10 Comprehensive Molecular Profiling and Comparison of Common and Rarer Subtypes of Lung Cancer
Authors: C. Domingo-Sabugo, E. Starren, A. Mandal, A. Nastase, L. Hoang, M. Edwards, D. Morris-Rosendahl, E. Lim, A. Nicholson, M. Lathrop, W. Cookson, M. Moffatt
Journal: Journal of Thoracic Oncology (2019)
P2.16-25 Epidemiology of Advanced Lung Cancer in Peru
Authors: R. Ruiz, M. Galvez Nino, K. Roque Perez, J. Moreno, N. Valdivieso, M. Olivera, J. Rivera, E. Amorin, L. Raez, L. Mas
Journal: Journal of Thoracic Oncology (2019)
P2.05-09 FDG-PET for Predicting Acute Exacerbation of Interstitial Pneumonia After Lung Cancer Surgery
Authors: K. Shimizu, S. Nakazawa, K. Numajiri, N. Kawabata, K. Obayashi, T. Ibe, T. Yajima, K. Shirabe
Journal: Journal of Thoracic Oncology (2019)
P1.09-16 Tumor Proliferation Is Associated with the Tumor Immunological Status: A Study on NSCLC Using Multiplex Immunofluorescence
Authors: A. Spitzmüller, T.H. Tan, M. Surace, L. Rognoni, D. Chain, V. Pawar, J. Rodriguez Canales
Journal: Journal of Thoracic Oncology (2019)
P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC
Authors: C. Teixido, C. Cabrera, A. Rodríguez, A. Arcocha, T. Pascual, A. Gimenez-Capitan, E. Marin, R. Reyes, C. Aguado, A.I. Martinez-Muñoz, N. Viñolas, B. Oñate, D. Martinez, M.A. Molina-Vila, A. Prat, N. Reguart
Journal: Journal of Thoracic Oncology (2019)
Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia
Authors: Steven Peter Treon, Christina K Tripsas, Kirsten Meid, Steven J Cropper, Patrick Mostyn, Diane Warren, Claudia E. Paba-Prada, Christopher Patterson, Guang Yang, Zachary Hunter, Janet Kunsman, Sandra Kanan, Irene M. Ghobrial
Journal: Blood (2013)
P1.04-13 Delineating Spatial Heterogeneity of Tumor Mutational Burden (TMB) Counts in Pulmonary Adenocarcinoma
Authors: D. Kazdal, M. Allgäuer, J. Budczies, M. Kriegsmann, J. Leichsenring, A. Volckmar, M. Kirchner, O. Neumann, R. Brandt, E. Rempel, S. Tala, A. Harms, C. Plögler, M. Von Winterfeld, R. Penzel, P. Schirmacher, V. Endris, A. Stenzinger
Journal: Journal of Thoracic Oncology (2019)